Literature DB >> 28878829

The Antibodies: What a Universe!

Mircea Cinteza1.   

Abstract

Year:  2017        PMID： 28878829      PMCID： PMC5574068     

Source DB:  PubMed          Journal:  Maedica (Bucur)        ISSN： 1841-9038


× No keyword cloud information.
  5 in total

1.  Reducing LDL with PCSK9 Inhibitors--The Clinical Benefit of Lipid Drugs.

Authors:  Brendan M Everett; Robert J Smith; William R Hiatt
Journal:  N Engl J Med       Date:  2015-10-07       Impact factor: 91.245

Review 2.  Cancer-testis antigens and immunotherapy in the light of cancer complexity.

Authors:  F Grizzi; L Mirandola; D Qehajaj; E Cobos; J A Figueroa; M Chiriva-Internati
Journal:  Int Rev Immunol       Date:  2015-03       Impact factor: 5.311

3.  A new era in cancer immunotherapy: discovering novel targets and reprogramming the immune system.

Authors:  Maurizio Chiriva-Internati; Adrian Bot
Journal:  Int Rev Immunol       Date:  2015-03       Impact factor: 5.311

4.  In This Issue: Translational Opportunities for Antibodies: Therapeutics, Biomarkers, and Novel Targets.

Authors:  Adrian Bot; Himanshu Kumar
Journal:  Int Rev Immunol       Date:  2016-07-03       Impact factor: 5.311

5.  Phase 1 Results of ZUMA-1: A Multicenter Study of KTE-C19 Anti-CD19 CAR T Cell Therapy in Refractory Aggressive Lymphoma.

Authors:  Frederick L Locke; Sattva S Neelapu; Nancy L Bartlett; Tanya Siddiqi; Julio C Chavez; Chitra M Hosing; Armin Ghobadi; Lihua E Budde; Adrian Bot; John M Rossi; Yizhou Jiang; Allen X Xue; Meg Elias; Jeff Aycock; Jeff Wiezorek; William Y Go
Journal:  Mol Ther       Date:  2017-01-04       Impact factor: 11.454
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.